{
  "id": "902f6679e491f8ab",
  "title": "STAT+: BioMarin to buy Amicus Therapeutics for $4.8B, bringing together rare disease biotechs",
  "description": "BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn of the century.",
  "content": "BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn of the century.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2025/12/19/biomarin-amicus-acquisition-rare-disease-fabry-pompe/?utm_campaign=rss",
  "published_at": "2025-12-19T13:24:38+00:00",
  "fetched_at": "2025-12-20T00:22:03.659749+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": null,
  "raw_data": {
    "title": "STAT+: BioMarin to buy Amicus Therapeutics for $4.8B, bringing together rare disease biotechs",
    "description": "BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn of the century.",
    "url": "https://www.statnews.com/2025/12/19/biomarin-amicus-acquisition-rare-disease-fabry-pompe/?utm_campaign=rss",
    "published": "2025-12-19T13:24:38+00:00",
    "source": "STAT"
  }
}